Innoviva

INVA • NASDAQ •
Overview Stats Financials News

Yahoo Finance • 10 months ago

Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics

Signs new $25 million credit agreement and extension of existing secured convertible credit agreement Appoints world‐renowned healthcare leader Dr. Deborah L. Birx as Chief Executive Officer MARINA DEL REY, Calif., July 11, 2023 /PRNewsw... Full story

Yahoo Finance • 10 months ago

12 Best Extremely Profitable Stocks to Buy

In this piece, we will take a look at 12 best extremely profitable stocks to buy. If you want to skip our economic and market analysis and jump ahead to the top five stocks in the list, take a look at 5 Best Extremely Profitable Stocks to... Full story

Yahoo Finance • a year ago

Innoviva Announces Retirement of Board Chairman

BURLINGAME, Calif., April 28, 2023--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" and "the Company") and George Bickerstaff, III, Chairman of the Board of Directors of the Company (the "Board") today announced that Mr. Bickers... Full story

Yahoo Finance • a year ago

12 Most Undervalued Pharma Stocks To Buy According To Hedge Funds

In this article, we discuss 12 most undervalued pharma stocks to buy according to hedge funds. If you want to see more stocks in this selection, check out 5 Most Undervalued Pharma Stocks To Buy According To Hedge Funds. Fitch Ratings has... Full story

Yahoo Finance • 2 years ago

Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at IDWEEK 2022

WALTHAM, Mass., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc., a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, and wholly owned subsidiary o... Full story

Yahoo Finance • 2 years ago

Royalty Pharma Agrees to Acquire Royalty Interest in TRELEGY ELLIPTA From Theravance and Innoviva for $1.31 Billion and Potential Milestones of $300 Million

Further diversifies Royalty Pharma’s portfolio with market-leading respiratory therapy Expected to significantly add to long-term Adjusted Cash Receipts growth(1) (non-GAAP) NEW YORK, July 13, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc... Full story

Yahoo Finance • 2 years ago

ENTASIS ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of ETTX and Encourages Investors to Contact the Firm

NEW YORK, May 24, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Entasis Therapeutics Holdings Inc. (NASD... Full story

Yahoo Finance • 2 years ago

Armata Pharmaceuticals Announces Closing of Second and Final Tranche of $45 Million Private Placement with Innoviva

MARINA DEL REY, Calif., March 31, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant... Full story